Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell, Inc. (NASDAQ: OMCL) has announced a significant seven-year sole source agreement with Lehigh Valley Health Network (LVHN), focusing on enhancing medication management efficiency and safety through Omnicell's advanced solutions. This partnership marks Omnicell's 142nd relationship with a top US health system. LVHN will utilize automated dispensing systems to streamline pharmacy operations and improve patient care. The aim is to create a fully-autonomous pharmacy, enhancing workflow and clinical outcomes.
Omnicell (NASDAQ: OMCL) announced that Memorial Hospital at Gulfport has selected its Central Pharmacy Dispensing Service, part of its medication management platform, to enhance pharmacy operations. This service incorporates the XR2 robotic dispensing technology, aiming to decrease dispensing errors and improve inventory management. The partnership seeks to allow hospital staff to concentrate more on patient care and operational efficiency, aligning with Memorial's mission of delivering high-quality patient experience.
Omnicell (NASDAQ:OMCL) has completed the acquisition of Pharmaceutical Strategies Group's (PSG) 340B Link business for $225 million. This acquisition enhances Omnicell's portfolio with software-enabled solutions aimed at helping hospitals and clinics manage compliance and capture drug cost savings under the federal 340B Drug Pricing Program. The 340B Link business generated approximately $35 million in revenue over the past year. The transaction is expected to be immediately accretive to non-GAAP earnings per share, financed through cash and a $575 million convertible senior notes offering.
Omnicell, Inc. (NASDAQ:OMCL) will host a conference call on October 27, 2020, at 1:30 p.m. PT to discuss its Third Quarter 2020 financial results. The call will feature Randall Lipps, the company’s CEO, and Peter Kuipers, CFO. Interested parties can participate by calling 1-800-696-5518 in the U.S. or 1-706-758-4883 internationally. A webcast will also be available on Omnicell’s investor relations website. A replay will be accessible from October 27, 2020, at 4:30 p.m. PT through November 24, 2020.